SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corgentech (CGTK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (13)11/16/2004 7:30:27 PM
From: Archie Meeties   of 39
 
Graft failure is biphasic. There is an initial drop off secondary to technical problems in the surgery, suboptimal graft stock, and graft spasm. This is followed then a long latent period, and then accelerated failure as grafts occlude (often from atherosclerotic plaques and collagen deposition). Hence, 5 year graft survival is 75%.

You would hypothesize that changes in graft survival at one year would be hard to demonstrate because of these confounding variables (technique, etc). Changes at one year (actually even just 6 months) in vein thickness (although not graft lumen diameter) and in remodeling should be much easier to show if ef2 inhibition is effective. That they could demonstrate differences in graft survival at 1 year seems significant.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News